The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an ...

MELBOURNE, Australia — The use of IDegLira, a fixed-ratio combination of the glucagonlike peptide (GLP)-1 receptor agonist liraglutide (Victoza, Novo Nordisk) and insulin degludec (Tresiba, Novo ...

ORLANDO, Fla. — Using fixed-ratio insulin combinations (FRC) can reduce side effects such as nausea in treating diabetes, an advantage that should persuade clinicians to consider these drugs more ...

A new study demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in ...

Mark Warren, MD: The DUAL VII trial was fascinating. They took patients who were not controlled on basal insulin, they randomized them to receive either multiple daily injections with a basal plus a ...

COPENHAGEN (Reuters) - Studies showed Novo Nordisk's insulin degludec lowered blood sugar levels with significantly reduced rates of hypoglycaemia when compared with rival Sanofi's Lantus, the Danish ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky for those with type 1 diabetes, the phase III QWINT-2 and -5 trials showed.

An investigational antidiabetic agent proved both non-inferior and superior to insulin for type 2 diabetes management, according to findings of the phase III SURPASS-3 trial. Over the course of the 52 ...

The fixed combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since June 2015 also in adults with type 2 diabetes mellitus when oral antidiabetics ...